Morepen Laboratories Limited (BOM:500288)
India · Delayed Price · Currency is INR 35.57
+0.94 (2.71%)
At close: Jan 22, 2026
Morepen Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 17,554 | 18,116 | 16,904 | 14,175 | 15,468 | 11,881 | Upgrade |
Other Revenue | 6.29 | - | - | 44.76 | 89.77 | 99.35 | Upgrade |
| 17,561 | 18,116 | 16,904 | 14,220 | 15,558 | 11,980 | Upgrade | |
Revenue Growth (YoY) | -1.05% | 7.17% | 18.88% | -8.60% | 29.87% | 39.57% | Upgrade |
Cost of Revenue | 11,612 | 11,854 | 10,858 | 9,750 | 10,611 | 7,882 | Upgrade |
Gross Profit | 5,949 | 6,262 | 6,047 | 4,470 | 4,947 | 4,098 | Upgrade |
Selling, General & Admin | 2,150 | 2,118 | 1,935 | 1,654 | 1,724 | 1,407 | Upgrade |
Other Operating Expenses | 2,460 | 2,403 | 2,525 | 1,976 | 1,766 | 1,406 | Upgrade |
Operating Expenses | 5,027 | 4,811 | 4,795 | 3,910 | 3,767 | 3,116 | Upgrade |
Operating Income | 921.74 | 1,451 | 1,252 | 560.79 | 1,180 | 981.65 | Upgrade |
Interest Expense | -136.74 | -77.85 | -37.1 | -19.81 | -24.26 | -17.88 | Upgrade |
Interest & Investment Income | 48.15 | 48.15 | 25.04 | 16.57 | 13.3 | 21.34 | Upgrade |
Currency Exchange Gain (Loss) | 102.95 | 102.95 | 96.97 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | 26.97 | 26.97 | 17.7 | - | 97.92 | - | Upgrade |
EBT Excluding Unusual Items | 963.07 | 1,551 | 1,354 | 557.55 | 1,267 | 985.12 | Upgrade |
Other Unusual Items | 258.25 | - | - | - | - | - | Upgrade |
Pretax Income | 1,221 | 1,551 | 1,354 | 557.55 | 1,267 | 985.12 | Upgrade |
Income Tax Expense | 226.83 | 370.94 | 387.95 | 170.8 | 250.21 | 14.22 | Upgrade |
Earnings From Continuing Operations | 994.49 | 1,180 | 966.2 | 386.76 | 1,017 | 970.9 | Upgrade |
Minority Interest in Earnings | 8.32 | 0.05 | -4.6 | -0 | 0.01 | -0.04 | Upgrade |
Net Income | 1,003 | 1,180 | 961.6 | 386.75 | 1,017 | 970.86 | Upgrade |
Net Income to Common | 1,003 | 1,180 | 961.6 | 386.75 | 1,017 | 970.86 | Upgrade |
Net Income Growth | -23.62% | 22.73% | 148.64% | -61.97% | 4.74% | 189.13% | Upgrade |
Shares Outstanding (Basic) | 555 | 535 | 511 | 502 | 450 | 450 | Upgrade |
Shares Outstanding (Diluted) | 555 | 535 | 511 | 502 | 520 | 451 | Upgrade |
Shares Change (YoY) | 6.75% | 4.71% | 1.79% | -3.39% | 15.24% | 0.28% | Upgrade |
EPS (Basic) | 1.81 | 2.20 | 1.88 | 0.77 | 2.26 | 2.16 | Upgrade |
EPS (Diluted) | 1.80 | 2.20 | 1.88 | 0.77 | 1.96 | 2.15 | Upgrade |
EPS Growth | -28.60% | 17.02% | 144.16% | -60.71% | -8.84% | 188.01% | Upgrade |
Free Cash Flow | -893.64 | -919.76 | 19.94 | -1,268 | -1,057 | 290.26 | Upgrade |
Free Cash Flow Per Share | -1.61 | -1.72 | 0.04 | -2.52 | -2.03 | 0.64 | Upgrade |
Dividend Per Share | - | 0.200 | - | - | - | - | Upgrade |
Gross Margin | 33.88% | 34.57% | 35.77% | 31.44% | 31.80% | 34.20% | Upgrade |
Operating Margin | 5.25% | 8.01% | 7.40% | 3.94% | 7.58% | 8.19% | Upgrade |
Profit Margin | 5.71% | 6.51% | 5.69% | 2.72% | 6.54% | 8.10% | Upgrade |
Free Cash Flow Margin | -5.09% | -5.08% | 0.12% | -8.92% | -6.79% | 2.42% | Upgrade |
EBITDA | 1,218 | 1,620 | 1,586 | 840.09 | 1,456 | 1,284 | Upgrade |
EBITDA Margin | 6.93% | 8.94% | 9.38% | 5.91% | 9.36% | 10.72% | Upgrade |
D&A For EBITDA | 295.91 | 168.69 | 334.7 | 279.3 | 276.43 | 302.83 | Upgrade |
EBIT | 921.74 | 1,451 | 1,252 | 560.79 | 1,180 | 981.65 | Upgrade |
EBIT Margin | 5.25% | 8.01% | 7.40% | 3.94% | 7.58% | 8.19% | Upgrade |
Effective Tax Rate | 18.57% | 23.91% | 28.65% | 30.63% | 19.75% | 1.44% | Upgrade |
Revenue as Reported | 17,744 | 18,299 | 17,044 | 14,237 | 15,571 | 12,001 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.